NEWS

• Quotient Sciences Proprietary AI-Enhanced Solution Optimizes Formulation In Clinical Study

  Quotient Sciences, a global integrated CRDMO (contract research, development and manufacturing organization), today reported interim results from a clinical study in which a proprietary artificial intelligence (AI) algorithm selected modified-release formulation compositions and doses during the trial. The algorithm reached the study's preset pharmacokinetic target within three dosing periods, meeting the program's interim objectives.

• Avance Clinical Appoints Inaugural Chief Commercial Officer, Reinforcing Global Growth Strategy

  Avance Clinical, a global full-service CRO headquartered in Australia dedicated to servicing international biotechs, today announced the appointment of Tim Schuckman as its first Chief Commercial Officer (CCO). Schuckman joined the company on Monday 17 August in a newly created executive role that reflects Avance Clinical’s continued growth, deeper client partnerships, and expanding presence across North America, Asia, and Europe.

• Ypsomed Opens Production Site In China
• Ypsomed Launches YpsoLoop As The First Autoinjector Platform Designed For Circularity
• Ypsomed Expands Offering For Clinical Studies
• Ypsomed Receives The Red Dot Design Award 2026 For YpsoLoop
• Ypsomed Receives FDA Clearance For SmartPilot
• Signant Health Acquires Ametris To Create An End-To-End eCOA And Wearables Platform

  Signant Health announced its acquisition of Ametris (formerly ActiGraph), a global digital health solutions provider. This strategic acquisition unites industry-leading eCOA solutions with validated, wearable-derived digital outcome measures.

• Avance Clinical Announces Asia Pacific And Mainland China Expansion Ahead Of BIO International Convention 2026

  Avance Clinical, the Australian-headquartered global Contract Research Organization (CRO) for biotechs, today announced a significant expansion of its Asia Pacific and China operations, reinforcing its position as the leading CRO partner for international biotech companies seeking access to the region’s diverse patient populations, scientific infrastructure, and accelerated clinical trial timelines.

• The Ottawa Hospital's Biotherapeutics Manufacturing Centre (BMC) Makes Breakthroughs Break Through As Boreal Biomanufacturing

  The Ottawa Hospital’s Biotherapeutics Manufacturing Centre (BMC), a facility that has developed more than 20 distinct cell- and virus-based products for human clinical trials in Canada, the United States, Europe and Asia, is becoming Boreal Biomanufacturing (Boreal). 

• Suvoda Patient App Earns "Best Patient Relationship Management Solution" In 2026 MedTech Breakthrough Awards Program

  MedTech Breakthrough, an independent market intelligence organization that recognizes the most innovative companies, technologies, and products in the global digital health and medical technology market, today announced that Suvoda, a global leader in clinical trial technology, has been selected as winner of the “Best Patient Relationship Management Solution” award in the 10th annual MedTech Breakthrough Awards program.

• Quotient Sciences Advances AI-Designed Drug Product Into Clinical Development
• Paradigm Health Announces Collaboration With The FDA To Transform Regulatory Review Of Clinical Trial Data

  The initiative will be implemented in two trials, using Paradigm Health’s integrated technology platform to accelerate FDA review.

• Inside Information: Nanoform Signs First Exclusivity Agreement For Ultra-High Concentration Subcutaneous Delivery

  Helsinki, Finland – Nanoform Finland Plc (“Nanoform”), the medicine performance‑enhancing company, today announced that it has signed an exclusivity agreement with a U.S. biopharmaceutical company (Nasdaq listed, Mcap USD 1Bn+) for the application of Nanoform’s proprietary biologics nanoparticle technology to support the development of differentiated subcutaneous biologic medicines.